Streetbeat News

TLTFF

Theralase Technologies Inc.

http://theralase.com/

CEO

Roger Dumoulin-White

Industry

Surgical and Medical Instrument Manufacturing

Open

0.16

Mkt cap

37M

Volume

21K

High

0.16

P/E Ratio

-15.00

52-wk high

0.27

Low

0.14

Div yield

N/A

52-wk low

0.08

Theralase Technologies Inc is advancing its Study II clinical trial for treating BCG-unresponsive non-muscle invasive bladder cancer with a light-activated small molecule. The company has enrolled and treated 75 patients, showing promising outcomes.

Portfolio Pulse from

November 28, 2024 | 2:00 pm

Theralase Technologies Inc has completed a private placement, raising $666,400 to support its Phase 2 bladder cancer study. The placement involved issuing 2,221,334 units at $0.30 each, with each unit comprising one common share and a warrant for an additional share at $0.45.

Portfolio Pulse from

November 15, 2024 | 2:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.